Yazar "Gevaert, Thomas" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment
    (ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD, 2018) Gevaert, Thomas; Montironi, Rodolfo; Lopez-Beltran, Antonio; Van Leenders, Geert; Allory, Yves; De Ridder, Dirk; Claessens, Frank
    Immunotherapy is gradually becoming a key factor in the therapeutic algorithm for patients with genito-urinary (GU) cancers at different stages of disease. Robust and reliable biomarkers are crucial for an appropriate inclusion of patients in clinical trials and for a reliable patient selection for treatments with immunomodulatory drugs. The increasing knowledge on the genomic landscape of GU cancers supports stratification of patients for targeted therapies. This review focusses on emerging biomarkers and the role of genomics in predicting clinical benefit to immunomodulatory agents in GU cancers. Based on cancer incidences and available data we restricted this overview to bladder, prostate and renal cancer.
  • Küçük Resim
    Öğe
    No survival difference between super extended and standard lymph node dissection at radical cystectomy: what can we learn from the first prospective randomized phase III trial?
    (AME PUBL CO, 2019) Muilwijk, Tim; Akand, Murat; Gevaert, Thomas; Joniau, Steven
    [Abstract not Available]
  • Küçük Resim
    Öğe
    Prognostic score predicts overall survival following complete urinary tract extirpation
    (TAYLOR & FRANCIS LTD, 2020) Akand, Murat; Muilwijk, Tim; Van Der Aa, Frank; Gevaert, Thomas; Milenkovic, Uros; Moris, Lisa; Blyweert, Wim; Poppel, Hendrik Van; Albersen, Maarten; Joniau, Steven
    Purpose: To evaluate the oncological outcome and complications of patients treated with complete urinary tract extirpation (CUTE) in our department, and to identify prognostic factors for survival. Methods: Clinico-pathological data of patients treated with one-step or stepwise CUTE between 1999 and 2017 were collected retrospectively. Complications were classified according to the modified Clavien-Dindo classification (CDC) in the early (<= 30 days) and late (>30 days) follow-up. Log-rank test was used to assess independent predictors of overall survival (OS), cancer-specific survival (CSS) and recurrence-free survival (RFS). Results: Twenty-five patients (20 male) underwent CUTE (16 one-step) for BC + unilateral/bilateral UTUC. Minor (CDC 1-2) and major (CDC3-5) complications were observed in 72% and 40% of patients, respectively, in the early postoperative period (<= 30 days). Five (20%) patients died in the perioperative period (CDC 5) with a median OS of 52 days (range: 25-77). Median time to last follow-up or death was 30 months (range: 0-161). Median OS was 50 months (95% Confidence Interval [CI]: 22-118 months), while median CCS and RFS were not reached. The 5-year OS, CSS and RFS were 42.7%, 69.6% and 66.7%, respectively. A score for determining which patients would benefit from CUTE was arbitrarily developed, and showed that the patients with a score of 0-2 points (good prognosis) had a better OS than the patients with a poor prognosis (3-4 points) in the log-rank test. Conclusions: Because of lower OS rates, patients with ESRD or with a CUTE score of 3-4 points are probably not ideal candidates for CUTE.